Printed From:

Interactive Dosing Calculator

Enter a weight to calculate the appropriate starting dose for your patient.
Weight (lb) / 2.2
= Kg x 0.2 = Unitsa
Please enter weight. Please enter a weight of 110 lbs or more.

aUnits of Lantus® are rounded down to the nearest whole unit.

From Lantus® Prescribing Information.

Lantus® Dosing

  • In a clinical trial of insulin-naïve patients poorly controlled on 1-2 OADs, average dose to achieve glycemic control with Lantus®: 47 Units2
  • Individualize dose based on the type of diabetes and whether the patient is insulin-naïve1
  • Administer Lantus® subcutaneously once a day at any time of the day, but at the same time every day
  • Converting from other insulin therapies may require adjustment of timing and dose of Lantus®
  • Closely monitor glucose values, especially upon converting to Lantus® and during the initial weeks thereafter

Two options to start Lantus®

Weight-based dosing: 0.2 Units/kg per day


Start with 10 Units per day of basal insulin

Start Lantus® at an appropriate dose for each patient

For patients with type 1 diabetes, the recommended starting dose of Lantus® should be approximately 1/3 of the total daily insulin requirements. For patients with type 1 diabetes, Lantus® must be used with a short-acting insulin. For insulin-naïve patients with type 2 diabetes, the recommended starting dose is 10 Units (or 0.2 Units/kg) once daily, and should be adjusted to the patients' needs to reach appropriate FPG target (ie, 100 mg/dL or individualized goal).

Initiating Lantus® in insulin-naïve and switched patients


  1. Lantus® Prescribing Information. February 2015.
  2. Riddle MC, Rosenstock J, Gerich J. Diabetes Care. 2003;26(11):3080-3086.

Proven HbA1c control

See how Lantus® provides effective, improved glycemic control in diabetes patients.

Lantus® Prescribing Information. February 2015.

Once-daily dosing

Lantus® is a once-daily, long-acting insulin.**

**Lantus® Prescribing Information. February 2015.

Demonstrated long-term CV safety

Lantus® is a basal insulin with demonstrated long-term CV safety data††

Including CV death, nonfatal MI, nonfatal stroke, revascularization, or hospitalization for heart failure. No difference was observed between Lantus® and standard of care in overall incidence of CV death, nonfatal MI, or nonfatal stroke. No difference was observed between treatment groups for death of any cause.